Jaron L. Winston - Concepedia

Author

Jaron L. Winston

Ben-Gurion University of the Negev

Also Known As

J. Goldstein, J. Winston, Janet Winston, Jaron L. Winston, Jaron Winston, Paul Winner

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Ben-Gurion University of the Negev Ralph H. Johnson VA Medical Center Medical University of South Carolina Tel Aviv University Harvard University

About

Jaron L. Winston is an author at Ben-Gurion University of the Negev specializing in medicine, health sciences, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	110
2	Health Sciences	2	2	95
3	Gastroenterology	1	1	82
4	Nephrology	1	1	15
5	Neurology	1	1	13

Jaron L. Winston

Publications

883

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial Yechiel Levkovitz, Moshe Isserles, Frank Padberg, World Psychiatry	2015	410
Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double‐blind randomized controlled trial Abraham Zangen, Hagar Moshe, Diana Martínez, World Psychiatry	2021	214
Amyloid-β <sup>11</sup> C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials Enchi Liu, Mark E. Schmidt, Richard Margolin, Neurology	2015	149
Methylnaltrexone Treatment of Opioid-Induced Constipation in Patients with Advanced Illness Bruce Chamberlain, Karen L. Cross, Jaron L. Winston, Journal of Pain and Symptom Management Functional Gastrointestinal DisorderPain MedicineAddictionMedicineGastroenterology	2009	82
An Open-Label, Randomized, Multicenter, Controlled Study of Epoetin Alfa for the Treatment of Anemia of Chronic Kidney Disease in the Long Term Care Setting Meenakshi Patel, David G. Thimons, Jaron L. Winston, Journal of the American Medical Directors Association HemodialysisLong Term CareRenal DiseaseRenal FunctionKidney Failure	2010	15
P2‐377: A phase 2, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL‐108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment Donald E. Schmechel, Gary Gerard, Nick G. Vatakis, Alzheimer s & Dementia Brain FunctionNeurochemical BiomarkersSynaptic SignalingAlzheimer's DiseaseSynaptic Neuroscience	2008	13

Page 1